These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15039314)

  • 1. N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice.
    Liu D; Gu X; Scafidi J; Davis AE
    Infect Immun; 2004 Apr; 72(4):1946-55. PubMed ID: 15039314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide.
    Liu D; Cai S; Gu X; Scafidi J; Wu X; Davis AE
    J Immunol; 2003 Sep; 171(5):2594-601. PubMed ID: 12928411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.
    Liu D; Cramer CC; Scafidi J; Davis AE
    Infect Immun; 2005 Aug; 73(8):4478-87. PubMed ID: 16040958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C1 inhibitor suppresses the endotoxic activity of a wide range of lipopolysaccharides and interacts with live gram-negative bacteria.
    Mejia P; Davis AE
    Shock; 2012 Aug; 38(2):220-5. PubMed ID: 22576004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor.
    Zhang H; Li J; Barrington RA; Liang G; Qin G; Liu DX
    Biochem Biophys Res Commun; 2007 Jul; 359(2):285-91. PubMed ID: 17543887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability.
    Liu D; Zhang D; Scafidi J; Wu X; Cramer CC; Davis AE
    Blood; 2005 Mar; 105(6):2350-5. PubMed ID: 15522962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C1 inhibitor-mediated protection from sepsis.
    Liu D; Lu F; Qin G; Fernandes SM; Li J; Davis AE
    J Immunol; 2007 Sep; 179(6):3966-72. PubMed ID: 17785834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.
    Cai S; Davis AE
    J Immunol; 2003 Nov; 171(9):4786-91. PubMed ID: 14568956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1 Inhibitor as a glycoprotein: The influence of polysaccharides on its function and autoantibody target.
    Ghannam A; Sellier P; Fain O; Martin L; Ponard D; Drouet C
    Mol Immunol; 2016 Mar; 71():161-165. PubMed ID: 26897339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes.
    Lotz M; Zuraw BL
    J Immunol; 1987 Nov; 139(10):3382-7. PubMed ID: 3119706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A direct role for C1 inhibitor in regulation of leukocyte adhesion.
    Cai S; Dole VS; Bergmeier W; Scafidi J; Feng H; Wagner DD; Davis AE
    J Immunol; 2005 May; 174(10):6462-6. PubMed ID: 15879149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5,6,7-trimethoxyflavone suppresses pro-inflammatory mediators in lipopolysaccharide-induced RAW 264.7 macrophages and protects mice from lethal endotoxin shock.
    Rim HK; Yun CH; Shin JS; Cho YW; Jang DS; Ryu JH; Park H; Lee KT
    Food Chem Toxicol; 2013 Dec; 62():847-55. PubMed ID: 24161485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock.
    Shi-Lin D; Yuan X; Zhan S; Luo-Jia T; Chao-Yang T
    Biochem Biophys Res Commun; 2015 Mar; 458(3):667-673. PubMed ID: 25684183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251.
    Zahedi R; Aulak KS; Eldering E; Davis AE
    J Biol Chem; 1996 Sep; 271(39):24307-12. PubMed ID: 8798678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular permeability of the cleaved reactive center loop within the carboxyl-terminal domain of C1 inhibitor.
    Cheng ZD; Liu MY; Chen G; Zhang HM; Qin GJ; Liang G; Liu DX
    Mol Immunol; 2008 Mar; 45(6):1743-51. PubMed ID: 18022239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency.
    Zhang F; Bries AD; Lang SC; Wang Q; Murhammer DW; Weiler JM; Linhardt RJ
    Biochim Biophys Acta; 2004 Dec; 1739(1):43-9. PubMed ID: 15607116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human C1-Inhibitor Suppresses Malaria Parasite Invasion and Cytoadhesion via Binding to Parasite Glycosylphosphatidylinositol and Host Cell Receptors.
    Mejia P; Diez-Silva M; Kamena F; Lu F; Fernandes SM; Seeberger PH; Davis AE; Mitchell JR
    J Infect Dis; 2016 Jan; 213(1):80-9. PubMed ID: 26347576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthetic cyclic peptide derived from Limulus anti-lipopolysaccharide factor neutralizes endotoxin in vitro and in vivo.
    Ren JD; Gu JS; Gao HF; Xia PY; Xiao GX
    Int Immunopharmacol; 2008 Jun; 8(6):775-81. PubMed ID: 18442780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous HMGB1 is required in endotoxin tolerance.
    Li S; Luo C; Yin C; Peng C; Han R; Zhou J; He Q; Zhou J
    J Surg Res; 2013 Nov; 185(1):319-28. PubMed ID: 23866790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor.
    Mandle R; Baron C; Roux E; Sundel R; Gelfand J; Aulak K; Davis AE; Rosen FS; Bing DH
    J Immunol; 1994 May; 152(9):4680-5. PubMed ID: 7512602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.